Mikolajczyk Adam E, Aronsohn Andrew I
Department of Medicine, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, IL.
Department of Medicine, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, IL.
Adv Chronic Kidney Dis. 2015 Sep;22(5):352-60. doi: 10.1053/j.ackd.2015.06.008.
The landscape of therapeutic options for hepatitis B and C has changed drastically over the course of 2 decades. There are now novel, effective, well-tolerated, oral antiviral agents being used to successfully control chronic hepatitis B (HBV) infections and cure chronic hepatitis C (HCV) infections. However, patients with CKD were rarely included in the Phase II and III randomized trials for these medications. This paucity of data and the high prevalence of comorbidities associated with CKD pose distinct challenges to physicians treating chronic hepatitis B virus and hepatitis C virus infections in the setting of kidney insufficiency/failure. Thus, this review will attempt to summarize the current data regarding novel antiviral therapies for HBV and HCV in the CKD population.
在过去20年里，乙型和丙型肝炎的治疗选择格局发生了巨大变化。目前，新型、有效、耐受性良好的口服抗病毒药物正被用于成功控制慢性乙型肝炎（HBV）感染并治愈慢性丙型肝炎（HCV）感染。然而，慢性肾脏病（CKD）患者很少被纳入这些药物的II期和III期随机试验。数据的匮乏以及与CKD相关的高合并症患病率给在肾功能不全/衰竭情况下治疗慢性乙型肝炎病毒和丙型肝炎病毒感染的医生带来了独特的挑战。因此，本综述将试图总结目前关于CKD人群中HBV和HCV新型抗病毒疗法的数据。
